(Reuters) - BioDelivery Sciences International Inc said it had received U.S. regulatory approval for its drug, Bunavail, to treat opioid dependence.
The company’s shares rose 8.5 percent to $10.85 in extended trading on Friday.
BioDelivery said it expects to launch the drug late in the third quarter ending Sept. 30.
Opioid dependence affects more than 2 million people in the United States.
Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel